PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.

AimIn Canada, staging of carcinoid tumors is largely based on computed tomography (CT) imaging sometimes complemented with somatostatin receptor scintigraphy (SRS). This study assessed the diagnostic accuracy of 6-[18F]fluoro-3,4-dihydroxyphenylalanine (18F-FDOPA) PET/CT in neuroendocrine tumors.Met